Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937902 | 0.96 | MEN1 (0.71) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL1188654 | 0.96 | MEN1 (0.71) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL1904635 | 0.96 | MEN1 (0.71) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL2769755 | 0.91 | MEN1 (0.64) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL7618274 | 0.88 | ALDH1A1 (0.72) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL6540812 | 0.86 | MEN1 (0.60) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL7181767 | 0.86 | MEN1 (0.60) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL7625352 | 0.86 | KDM4E (0.73) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL29297383 | 0.85 | ALDH1A1 (0.58) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL7484491 | 0.85 | MEN1 (0.80) | MEN1KMT2AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20170210749-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-07-27 | — | — | US | disclosed |
| US-9662327-B2 | Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-24 | — | — | US | disclosed |
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1137412-A4 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | AMERICAN BIOGENETIC SCIENCES (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1137412-A2 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000033788-A2 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | AMERICAN BIOGENETIC SCIENCES INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | MEN1 3465/4885KMT2A 1695/4885KDM4E 977/4885 |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | MEN1 868/4885KMT2A 3204/4885KDM4E 3587/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | MEN1 3465/4885KMT2A 1695/4885KDM4E 977/4885 |
| US-20170210749-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, GZMB, ANXA2 | MEN1 1225/4885KMT2A 2810/4885KDM4E 2992/4885 |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, GZMB, ANXA2 | MEN1 1225/4885KMT2A 2810/4885KDM4E 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.